by Jinghong Chen

Among various proposals to redesign the Medicare Part D benefit, both a bill from the Senate Finance Committee and a model from the Medicare Payment Advisory Commission (MedPAC) would change how drugs are financed in the catastrophic coverage phase and drive plans to better manage beneficiaries with high drug spending. The graphs below, from a recent analysis published in the New England Journal of Medicine, show estimated 2020 spending on brand-name and biosimilar drugs by payer under current and proposed Part D benefit designs for beneficiaries with $25,000 and $100,000 in drug spending.

SOURCE: “Proposals to Redesign Medicare Part D — Easing the Burden of Rising Drug Prices,” The New England Journal of Medicine, Sept. 4, 2019.